+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Osteoporosis Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4986955
  • Report
  • February 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Actavis plc
  • Amgen, Inc.
  • Eli Lily and Company
  • F. Hoffmann La Roche
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • MORE
The osteoporosis drugs market studied was predicted to grow with a CAGR of nearly 5.3% over the forecast period. The major factor accrediting to the growth of the market is increasing the incidence of osteoporosis. According to the National Osteoporosis Foundation, in 2018, an estimated 10 million have osteoporosis and another 44 million have low bone density, placing them at increased risk, in America. Rising geriatric population globally who are prone to low bone density is another main factor for the growth of the market. Furthermore, the growing investments in research and development programs by the biotechnology and pharmaceutical companies are boosting the market growth. However, the stringent regulations by the government are the major drawback for the market growth.

Key Market Trends

RANK Ligand Inhibitors Segment is expected to Dominate the Market
  • RANK ligand (RANKL) inhibitors are used for the management of osteoporosis in patients at high risk for bone fractures. The high growth possibility achieved is a result of positive patient results associated with rank ligand inhibitors. The positive patient outcomes can be credited to significant improvements in bone metabolism. Rank ligand inhibitors can also be utilized in combination with other drugs to impart a synergistic effect in the overall treatment regime. The above-mentioned factor is also anticipated to be one of the key factors accountable to present profitable opportunities. Other advantages relating to rank ligand inhibitors such as reduced cell bone turnover and increased bone mineral density, thereby implicating high demand.
  • Apart from the advantages of RANK ligand inhibitors, other factors that drive the segment growth are increasing geriatric population and increasing patient pool.
North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall osteoporosis drugs market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of osteoporosis patients in the region, established healthcare infrastructure, and availability of branded drugs are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth. In the North America region, the United States holds the largest market share due to factors such as an increasing number of geriatric populations, along with a growing number of patient pool in the country and several collaborative efforts commenced by major companies to enhance their abilities and guarantee high medical standards.

Competitive Landscape

The Osteoporosis Drugs market is moderately competitive and consists of several major players. Some of the companies which are currently domianting the market Pfizer, Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co., Inc., Amgen, Inc., Radius Health, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis International AG, Actavis plc.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4


  • Actavis plc
  • Amgen, Inc.
  • Eli Lily and Company
  • F. Hoffmann La Roche
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study




4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing incidences of osteoporosis
4.2.2 Rise in the geriatric populations
4.3 Market Restraints
4.3.1 Stringent regulatory environment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5.1 By Drug Type
5.1.1 Parathyroid Hormone Therapy
5.1.2 Bisphosphonates
5.1.3 Calcitonin
5.1.4 RANKL Inhibitors
5.1.5 Others
5.2 By Application
5.2.1 Primary Osteoporosis
5.2.2 Secondary Osteoporosis
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles
6.1.1 Pfizer, Inc.
6.1.2 Eli Lily and Company
6.1.3 F. Hoffmann La Roche
6.1.4 Merck & Co., Inc.
6.1.5 Amgen, Inc.
6.1.6 Radius Health, Inc.
6.1.7 Teva Pharmaceutical Industries Ltd.
6.1.8 GlaxoSmithKline plc
6.1.9 Novartis International AG
6.1.10 Actavis plc

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Pfizer, Inc.
  • Eli Lily and Company
  • F. Hoffmann La Roche
  • Merck & Co., Inc.
  • Amgen, Inc.
  • Radius Health, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Novartis International AG
  • Actavis plc
Note: Product cover images may vary from those shown